Aspirin resistance in vitro and hypertension in stroke patients [3]

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 11, 2004, Pages 2051-2053

  Macchi, L ^a   Petit, E ^a   Brizard, A ^a   Gil, R ^a   Neau, J P ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGE; AGED; BLOOD SAMPLING; BLOOD VISCOSITY; CELL INTERACTION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; ERYTHROCYTE AGGREGATION; FEMALE; HUMAN; HYPERTENSION; IN VITRO STUDY; LETTER; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SHEAR STRESS; THROMBOCYTE ACTIVATION;

AGED; ASPIRIN; BLOOD COAGULATION TESTS; CEREBROVASCULAR ACCIDENT; DRUG RESISTANCE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREVALENCE;

EID: 13244271939     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00953.x     Document Type: Letter

References (14)

1. Antiplatelets Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-3.
3. Jilma B, Fuchs I. Methods to assess aspirin resistance. J Thromb Haemost 2004; 2: 337-8.
4. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients: evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63: 587-93.
5. Helgason CM, Tortorice KL, Winckler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD. Aspirin response and failure in cerebral infarction. Stroke 1993; 24: 345-50.
6. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
7. Hegalson CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
8. Gum PA, Kottke-Marchand K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88 230-5.
9. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63-6.
10. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III and the TOAST Investigators. Classification of subtypes of acute ischaemic stroke. Definition for use in a multicenter clinical trial. Stroke 1993; 24: 35-41.
11. Alberts MJ, Bergmann DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004; 35: 175-8.
12. A1 (GP IIIa) polymorphism but not with C807T (GP Ia-IIa) and C-5T Kozak (GP Ibα) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-9.
13. Lominadze D, Schuschke DA, Joshua IG, Dean WL. Increased ability of erythrocytes to aggregate in spontaneously hypertensive rats. Clin Exp Hypertens 2002; 24: 397-406.
14. Valles J, Santos T, Aznar J, Osa A, Lago A, Cosin J, Sanchez E, Broekman J, Marcus AJ. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350-5.